BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29303069)

  • 1. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
    Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
    Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Amyloidosis: Diagnosis and Treatment Strategies.
    Tuzovic M; Yang EH; Baas AS; Depasquale EC; Deng MC; Cruz D; Vorobiof G
    Curr Oncol Rep; 2017 Jul; 19(7):46. PubMed ID: 28528458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
    Koike H; Katsuno M
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options.
    Alkhawam H; Patel D; Nguyen J; Easaw SM; Al-Sadawi M; Syed U; Zaiem F; Homsi M; Vittorio TJ
    Acta Cardiol; 2017 Aug; 72(4):380-389. PubMed ID: 28705053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted treatments of AL and ATTR amyloidosis.
    Chandrashekar P; Desai AK; Trachtenberg BH
    Heart Fail Rev; 2022 Sep; 27(5):1587-1603. PubMed ID: 34783948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac amyloidosis.
    Quarta CC; Kruger JL; Falk RH
    Circulation; 2012 Sep; 126(12):e178-82. PubMed ID: 22988049
    [No Abstract]   [Full Text] [Related]  

  • 8. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial Amyloidosis: The Exemplar Interstitial Disease.
    Fontana M; Ćorović A; Scully P; Moon JC
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2345-2356. PubMed ID: 31422120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Advances in the Management of Cardiac Amyloidosis.
    Vranian MN; Sperry BW; Valent J; Hanna M
    Curr Cardiol Rep; 2015 Nov; 17(11):100. PubMed ID: 26374453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
    Siddiqi OK; Ruberg FL
    Trends Cardiovasc Med; 2018 Jan; 28(1):10-21. PubMed ID: 28739313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.
    Park MA; Padera RF; Belanger A; Dubey S; Hwang DH; Veeranna V; Falk RH; Di Carli MF; Dorbala S
    Circ Cardiovasc Imaging; 2015 Aug; 8(8):. PubMed ID: 26259579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatments for amyloidosis.
    Sayed RH; Hawkins PN; Lachmann HJ
    Kidney Int; 2015 Mar; 87(3):516-26. PubMed ID: 25469850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathy Associated with Systemic Amyloidosis.
    Kaku M; Berk JL
    Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in pharmacotherapy for cardiac amyloidosis.
    Spoladore R; Falasconi G; Marcatti M; Di Maio S; Fiore G; Slavich M; Margonato A; Turco A; Fragasso G
    Expert Opin Pharmacother; 2021 Mar; 22(4):469-481. PubMed ID: 33043721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
    Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pharmacotherapies for cardiac amyloidosis.
    Alexander KM; Singh A; Falk RH
    Pharmacol Ther; 2017 Dec; 180():129-138. PubMed ID: 28648829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
    Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
    Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.